Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Uridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.90 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.90 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.90 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.90 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.74 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL157643 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL30094506 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL29801499 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28065954 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL76681 | 1.00 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28131489 | 0.99 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL17074124 | 0.99 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2370972 | 0.99 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL17439380 | 0.95 | SLC28A1 (0.85) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL5330850 | 0.95 | SLC28A1 (0.85) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662350-B | Preparation method of green intelligent high-purity diquafosol tetrasodium | 南京宸翔医药研究有限责任公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2021117837-A1 | IONIC-GROUP-CONTAINING MICROBALLOON AND PRODUCTION METHOD THEREFOR | 株式会社トクヤマ | 2021-06-17 | — | — | WO | disclosed |
| CN-111662350-A | Preparation method of green intelligent high-purity diquafosol tetrasodium | 南京宸翔医药研究有限责任公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-110981928-A | Method for producing uridylic acid disodium by continuous flow reaction device | 美亚药业海安有限公司 | 2020-04-10 | — | — | CN | disclosed |
| CN-110885812-A | Method for preparing uridylic acid by enzyme method | 杭州唯泰生物药业有限公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-1644394-B1 | SYNTHESIS AND COMPOSITIONS OF 2 -TERMINATOR NUCLEOTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-1641943-B1 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | ROCHE DIAGNOSTICS GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8163487-B2 | 2′-terminator nucleotide-related methods and systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2076606-B1 | 2'-TERMINATOR RELATED PYROPHOSPHOROLYSIS ACTIVATED POLYMERIZATION | ROCHE DIAGNOSTICS GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110201002-A1 | 2'-Terminator Nucleotide-Related Methods and Systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-6765090-B2 | DRUGS; STABILITY, SOLUBILITY, NONTOXIC, EASY TO HANDLE | INSPIRE PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| US-6713458-B1 | DRY EYE; RETINAL DETACHMENT | INSPIRE PHARMACEUTICALS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1012154-B1 | SALTS OF DI(URIDINE 5'-TETRAPHOSPHATE), METHOD FOR PREPARATION AND USES THEREOF | INSPIRE PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20040014713-A1 | Di(uridine 5')-tetraphosphate and salts thereof | MERCK SHARP & DOHME CORP. | 2004-01-22 | — | — | US | disclosed |
| US-6548658-B2 | Tetrasodium, ammonium, lithium and potassium salts of P1, P4-di(uridine 5')-tetraphosphate; stable, soluble, nontoxic, of high purity and easy to handle during manufacture | INSPIRE PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020086851-A1 | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof | MERCK SHARP & DOHME CORP. | 2002-07-04 | — | — | US | disclosed |
| US-6319908-B1 | FOR THERAPY CYSTIC FIBROSIS, CHRONIC BRONCHITIS, ASTHMA, BRONCHIECTASIS, POST-OPERATIVE MUCOUS RETENTION, PNEUMONIA, PRIMARY CILIARY DYSKINESIA | INSPIRE PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010011079-A1 | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof | MERCK SHARP & DOHME CORP. | 2001-08-02 | — | — | US | disclosed |
| EP-1012154-A2 | SALTS OF DI(URIDINE 5'-TETRAPHOSPHATE), METHOD FOR PREPARATION AND USES THEREOF | Inspire Pharmaceuticals, Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999005155-A2 | SALTS OF DI(URIDINE 5'-TETRAPHOSPHATE), METHOD FOR PREPARATION AND USES THEREOF | INSPIRE PHARMACEUTICALS, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086851-A1 | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof | UMPS, NUDT1, ITPA | SLC28A1 45/4885SLC28A2 53/4885SLC29A1 34/4885 |
| US-20040014713-A1 | Di(uridine 5')-tetraphosphate and salts thereof | UMPS, NUDT1, UPP1 | SLC28A1 63/4885SLC28A2 110/4885SLC29A1 26/4885 |
| US-20010011079-A1 | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof | UMPS, NUDT1, UPP1 | SLC28A1 65/4885SLC28A2 111/4885SLC29A1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.